PLRX News | Roxom Stocks

1 BTC

- USD

Loading market data...

Mkt Cap

$55.7M

Volume

N/A

Next Earnings

November 5th

Chart Financials Earnings News About Insider Filings

Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual MeetingPliant Therapeutics presented updated Phase 1 trial data for PLN-101095, an integrin inhibitor combined with pembrolizumab, showing encouraging results in immune checkpoint inhibitor-refractory patients. The drug demonstrated confirmed responses with 89% average tumor reduction and 19-month median time on treatment. The company has initiated a Phase 1b expansion trial with interim data expected in 2027.GlobeNewswire Inc. · Apr 18, 2026

INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant TherapeuticsPliant Therapeutics has voluntarily paused enrollment and dosing in its ongoing BEACON-IPF Phase 2b trial of bexotegrast, leading to a significant drop in its stock price. Faruqi & Faruqi, LLP is investigating potential claims on behalf of investors who suffered significant losses.GlobeNewswire Inc. · Mar 23, 2025

Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary FibrosisPliant Therapeutics has voluntarily paused enrollment and dosing in the ongoing BEACON-IPF Phase 2b trial of bexotegrast for idiopathic pulmonary fibrosis, following a recommendation by the trial's independent Data Safety Monitoring Board. The company will monitor current patients while the data is reviewed.GlobeNewswire Inc. · Feb 7, 2025

Pliant Therapeutics Presents Data from its Bexotegrast Program at The Liver Meeting® 2024Pliant Therapeutics presented positive data from the INTEGRIS-PSC trial, showing that their drug bexotegrast improved markers and symptoms of cholestasis and stabilized liver fibrosis in patients with primary sclerosing cholangitis.GlobeNewswire Inc. · Nov 18, 2024

Pliant Therapeutics CBO sells shares worth over $114k - Investing.comPliant Therapeutics' Chief Business Officer Hans Hull sold 9,900 shares of the company's common stock, valued at over $114,000. The sale was part of a nondiscretionary plan to satisfy withholding tax liabilities related to the vesting of performance-vested stock units.Investing.com · Jul 13, 2024

These Analysts Revise Their Forecasts On Pliant Therapeutics Following Q1 EarningsPliant Therapeutics, Inc. (NASDAQ:PLRX) posted a loss for its first quarter on Monday. Pliant Therapeutics posted a quarterly loss of 78 cents per share, versus market expectations for a loss of 77 cents per share, according to data from Benzinga Pro. Research and development expenses rose to $37.1 million from $29.3 million for the year-ago quarter, while general and administrative expenses increased to $15.2 million from $14.2 million. “In the first quarter, we made significant progress across our portfolio, highlighted by the positive safety and exploratory efficacy ...Full story available on Benzinga.comBenzinga · May 7, 2024

Earnings Preview: Pliant Therapeutics, Inc. (PLRX) Q4 Earnings Expected to DeclinePliant Therapeutics, Inc. (PLRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.Zacks Investment Research · Mar 7, 2024

Why Air Products and Chemicals Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day SessionShares of Air Products and Chemicals, Inc. (NYSE: APD) fell sharply during Monday’s session after the company reported worse-than-expected first-quarter financial results and lowered FY24 adjusted EPS guidance below estimates. Air Products & Chemicals posted adjusted earnings of $2.82 per share, missing market estimates of $3.00 per share. The company’s quarterly sales came in at $3.00 billion versus expectations of $3.19 billion. Air Products and Chemicals shares dipped 14.7% to $220.02 on Monday. Here are some other stocks moving in today's mid-day session. Gainers Yield10 Bioscience, Inc. (NASDAQ: YTEN) shares climbed 116.4% to $0.4964. 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) gained 100.9% to $35.13 after the company announced interim data from the Phase 2 PRISM clinical trial evaluating intravitreal 4D-150 in wet AMD patients with severe disease activity and a high treatment burden. Chenghe Acquisition Co. (NASDAQ: CHEA) shares jumped 76% to $9.66 after shareholders on Friday voted to approve the merger agreement with Taiwan Color Optics. Wrap Technologies, Inc. (NASDAQ: WRAP) gained 55.6% to $6.35. Wrap Technologies has reduced its labor force by 30%, representing $2.4 million in annual savings. Adverum Biotechnologies, Inc. (NASDAQ: ADVM) climbed 31.1% to $1.8620. Adverum Biotechnologies has agreed to sell approximately 106.25 million shares in a private placement at $1.20 per share with gross proceeds of approximately $127.5 million. MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) surged 31.1% to $1.22. MIRA Pharmaceuticals announced a research collaboration with Pharmaseed to conduct pre-clinical studies on use of Ketamir for patients with major depressive disorder and post-traumatic stress disorder. Envoy Medical, Inc. (NASDAQ: COCH) rose 27% to $1.5261. Griid Infrastructure Inc. (NASDAQ: GRDI) shares rose 26.4% to $2.63 after dipping more ...Benzinga · Feb 5, 2024

HC Wainwright & Co. Maintains Buy Rating for Pliant Therapeutics: Here's What You Need To KnowHC Wainwright & Co. has decided to maintain its Buy rating of Pliant Therapeutics (NASDAQ:PLRX) and lower its price target from $52.00 to $48.00. Shares of Pliant Therapeutics are trading down 3.74% over the last 24 hours, at $16.75 per share. A move to $48.00 would account for a 186.57% increase from the current share price. About Pliant Therapeutics Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is ...Full story available on Benzinga.comBenzinga · Feb 5, 2024

The Latest Analyst Ratings for Pliant TherapeuticsPliant Therapeutics (NASDAQ:PLRX) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 5 2 0 0 0 Last 30D 0 1 0 0 0 1M Ago 0 0 0 0 0 2M Ago 4 0 0 0 0 3M Ago 1 1 0 0 0 According to 7 analyst offering 12-month price targets in the last 3 months, Pliant Therapeutics has an average price target of $50.43 with a high of $63.00 and a low of $45.00. Below is a summary of how ...Full story available on Benzinga.comBenzinga · Nov 10, 2023

PLRXPliant Therapeutics, Inc. Common Stock

PLRX

Pay with—

Start Trading

Available Balance0.00

Your PositionYou don't own any PLRX yet.

Related Tickers

Earnings

Mkt Cap

$58.1M

Next Earnings

November 5th